Aduhelm and the politics of drug approval in the United States
During the past several decades, the US Congress has authorized billions of dollars for Alzheimer’s disease research, but this has not yet led to a major breakthrough in the treatment. It is therefore understandable why there was a great deal of excitement about a new drug being developed by Biogen for the treatment of Alzheimer’s disease, aducanumab (Aduhelm).